Herbst, Roy SRoy SHerbstWu, Yi-LongYi-LongWuJohn, ThomasThomasJohnGrohe, ChristianChristianGroheMajem, MargaritaMargaritaMajemWang, JieJieWangKato, TerufumiTerufumiKatoGoldman, Jonathan WJonathan WGoldmanLaktionov, KonstantinKonstantinLaktionovKim, Sang-WeSang-WeKimCHONG-JEN YUVu, Huu VinhHuu VinhVuLu, ShunShunLuLee, Kye YoungKye YoungLeeMukhametshina, GuzelGuzelMukhametshinaAkewanlop, CharuwanCharuwanAkewanlopde Marinis, FilippoFilippode MarinisBonanno, LauraLauraBonannoDomine, ManuelManuelDomineShepherd, Frances AFrances AShepherdUrban, DamienDamienUrbanHuang, XiangningXiangningHuangBolanos, AnaAnaBolanosStachowiak, MartaMartaStachowiakTsuboi, MasahiroMasahiroTsuboi2023-04-202023-04-202023-04-010732-183X1527-7755https://scholars.lib.ntu.edu.tw/handle/123456789/630364The phase III ADAURA (ClinicalTrials.gov identifier: NCT02511106) primary analysis demonstrated a clinically significant disease-free survival (DFS) benefit with adjuvant osimertinib versus placebo in EGFR-mutated stage IB-IIIA non-small-cell lung cancer (NSCLC) after complete tumor resection (DFS hazard ratio [HR], 0.20 [99.12% CI, 0.14 to 0.30]; P < .001). We report an updated exploratory analysis of final DFS data.en[SDGs]SDG3journal article10.1200/JCO.22.02186367200832-s2.0-85149687912https://api.elsevier.com/content/abstract/scopus_id/85149687912